TXMD
TherapeuticsMD, Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$23M
5Y Perf.-96.4%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
TXMD vs DARE
Revenue, margins, valuation, and 5-year total return — side by side.
DARE
Daré Bioscience, Inc.
Biotechnology
Market Cap$25M
5Y Perf.-76.9%
TXMD vs DARE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | TXMD | DARE |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
| Market Cap | $23M | $25M |
| Revenue (TTM) | $3M | $-57K |
| Net Income (TTM) | $302K | $-17M |
| Gross Margin | 96.6% | -1461.1% |
| Operating Margin | -97.1% | -2396.9% |
| Total Debt | $7M | $1M |
| Cash & Equiv. | $5M | $16M |
TXMD vs DARE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
TXMD
DARE
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | 100 | 3.6 | -96.4% |
| Daré Bioscience, In… (DARE) | 100 | 23.1 | -76.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TXMD vs DARE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TXMD leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Daré Bioscience, Inc. is the stronger pick specifically for valuation and capital efficiency and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
TXMD
TherapeuticsMD, Inc.
The Growth Play
TXMD carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 35.3%, EPS growth 74.3%, 3Y rev CAGR -11.9%
- 35.3% revenue growth vs DARE's -99.7%
- 10.8% margin vs DARE's -414.3%
Best for: growth exposure
DARE
Daré Bioscience, Inc.
The Income Pick
DARE is the clearest fit if your priority is income & stability and long-term compounding.
- beta 0.48
- -99.0% 10Y total return vs TXMD's -99.5%
- Lower volatility, beta 0.48, current ratio 0.85x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | TXMD | 35.3% revenue growth vs DARE's -99.7% |
| Value | DARE | Better valuation composite |
| Quality / Margins | TXMD | 10.8% margin vs DARE's -414.3% |
| Stability / Safety | DARE | Beta 0.48 vs TXMD's 0.51 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | TXMD | +45.7% vs DARE's +0.7% |
| Efficiency (ROA) | TXMD | 0.8% ROA vs DARE's -56.8% |
TXMD vs DARE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2023
FY 2024
TXMD vs DARE — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLTXMDLAGGINGDARE
DAREDaré Bioscience, Inc.
0leads
TXMDTherapeuticsMD, Inc.
3leads
6 Total Categories
CATEGORYLEADERvs DAREMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
TXMD5/6
Valuation MetricsMultiples, price ratios, and targets
TXMD2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
TXMD4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
TXMD leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TXMD and DARE operate at a comparable scale, with $3M and -$57,130 in trailing revenue. TXMD is the more profitable business, keeping 10.8% of every revenue dollar as net income compared to DARE's -414.3%. On growth, TXMD holds the edge at +43.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | TXMDTherapeuticsMD, I… | DAREDaré Bioscience, … |
|---|---|---|
| RevenueTrailing 12 months | $3M | -$57,130 |
| EBITDAEarnings before interest/tax | -$2M | -$16M |
| Net IncomeAfter-tax profit | $302,000 | -$17M |
| Free Cash FlowCash after capex | $2M | -$7M |
| Gross MarginGross profit ÷ Revenue | +96.6% | -1461.1% |
| Operating MarginEBIT ÷ Revenue | -97.1% | -2396.9% |
| Net MarginNet income ÷ Revenue | +10.8% | -414.3% |
| FCF MarginFCF ÷ Revenue | +74.0% | +492.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +43.3% | -94.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +118.9% | +49.2% |
TXMD leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
TXMD leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | TXMDTherapeuticsMD, I… | DAREDaré Bioscience, … |
|---|---|---|
| Market CapShares × price | $23M | $25M |
| Enterprise ValueMkt cap + debt − cash | $25M | $11M |
| Trailing P/EPrice ÷ TTM EPS | -10.58x | -6.06x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 13.21x | 2587.71x |
| Price / BookPrice ÷ Book value/share | 0.85x | — |
| Price / FCFMarket cap ÷ FCF | 31.78x | 5.25x |
TXMD leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
TXMD leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
TXMD delivers a 1.1% return on equity — every $100 of shareholder capital generates $1 in annual profit, vs $-6 for DARE. On the Piotroski fundamental quality scale (0–9), TXMD scores 6/9 vs DARE's 4/9, reflecting solid financial health.
| Metric | TXMDTherapeuticsMD, I… | DAREDaré Bioscience, … |
|---|---|---|
| ROE (TTM)Return on equity | +1.1% | -6.1% |
| ROA (TTM)Return on assets | +0.8% | -56.8% |
| ROICReturn on invested capital | -11.4% | — |
| ROCEReturn on capital employed | -13.6% | -36.2% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 |
| Debt / EquityFinancial leverage | 0.26x | — |
| Net DebtTotal debt minus cash | $2M | -$14M |
| Cash & Equiv.Liquid assets | $5M | $16M |
| Total DebtShort + long-term debt | $7M | $1M |
| Interest CoverageEBIT ÷ Interest expense | -194.43x | -35.60x |
TXMD leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — TXMD and DARE each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DARE five years ago would be worth $1,757 today (with dividends reinvested), compared to $369 for TXMD. Over the past 12 months, TXMD leads with a +45.7% total return vs DARE's +0.7%. The 3-year compound annual growth rate (CAGR) favors TXMD at -19.7% vs DARE's -37.6% — a key indicator of consistent wealth creation.
| Metric | TXMDTherapeuticsMD, I… | DAREDaré Bioscience, … |
|---|---|---|
| YTD ReturnYear-to-date | +21.8% | +49.2% |
| 1-Year ReturnPast 12 months | +45.7% | +0.7% |
| 3-Year ReturnCumulative with dividends | -48.2% | -75.8% |
| 5-Year ReturnCumulative with dividends | -96.3% | -82.4% |
| 10-Year ReturnCumulative with dividends | -99.5% | -99.0% |
| CAGR (3Y)Annualised 3-year return | -19.7% | -37.6% |
Evenly matched — TXMD and DARE each lead in 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — TXMD and DARE each lead in 1 of 2 comparable metrics.
Risk & Volatility
DARE is the less volatile stock with a 0.48 beta — it tends to amplify market swings less than TXMD's 0.51 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TXMD currently trades 68.1% from its 52-week high vs DARE's 31.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | TXMDTherapeuticsMD, I… | DAREDaré Bioscience, … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.51x | 0.48x |
| 52-Week HighHighest price in past year | $2.95 | $9.19 |
| 52-Week LowLowest price in past year | $0.98 | $1.27 |
| % of 52W HighCurrent price vs 52-week peak | +68.1% | +31.7% |
| RSI (14)Momentum oscillator 0–100 | 43.3 | 70.2 |
| Avg Volume (50D)Average daily shares traded | 21K | 581K |
Evenly matched — TXMD and DARE each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | TXMDTherapeuticsMD, I… | DAREDaré Bioscience, … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
TXMD leads in 3 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 2 categories are tied.
Best OverallTherapeuticsMD, Inc. (TXMD)Leads 3 of 6 categories
Loading custom metrics...
TXMD vs DARE: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is TXMD or DARE a better buy right now?
For growth investors, TherapeuticsMD, Inc.
(TXMD) is the stronger pick with 35. 3% revenue growth year-over-year, versus -99. 7% for Daré Bioscience, Inc. (DARE). The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — TXMD or DARE?
Over the past 5 years, Daré Bioscience, Inc.
(DARE) delivered a total return of -82. 4%, compared to -96. 3% for TherapeuticsMD, Inc. (TXMD). Over 10 years, the gap is even starker: DARE returned -99. 0% versus TXMD's -99. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — TXMD or DARE?
By beta (market sensitivity over 5 years), Daré Bioscience, Inc.
(DARE) is the lower-risk stock at 0. 48β versus TherapeuticsMD, Inc. 's 0. 51β — meaning TXMD is approximately 7% more volatile than DARE relative to the S&P 500.
04Which is growing faster — TXMD or DARE?
By revenue growth (latest reported year), TherapeuticsMD, Inc.
(TXMD) is pulling ahead at 35. 3% versus -99. 7% for Daré Bioscience, Inc. (DARE). On earnings-per-share growth, the picture is similar: Daré Bioscience, Inc. grew EPS 88. 4% year-over-year, compared to 74. 3% for TherapeuticsMD, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — TXMD or DARE?
TherapeuticsMD, Inc.
(TXMD) is the more profitable company, earning -123. 9% net margin versus -414. 3% for Daré Bioscience, Inc. — meaning it keeps -123. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TXMD leads at -270. 3% versus -2396. 9% for DARE. At the gross margin level — before operating expenses — TXMD leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — TXMD or DARE?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is TXMD or DARE better for a retirement portfolio?
For long-horizon retirement investors, Daré Bioscience, Inc.
(DARE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 48)). Both have compounded well over 10 years (DARE: -99. 0%, TXMD: -99. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between TXMD and DARE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: TXMD is a small-cap high-growth stock; DARE is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(TXMD: 43.3% · DARE: -94.6%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.